Small Molecules

23 Oct 2017 Viking Therapeutics Presents Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) at the 87th Annual Meeting of the American Thyroid Association
23 Oct 2017 Madrigal Pharmaceuticals Presents Preclinical Results Supporting the Therapeutic Potential of its Lead β-Selective Thyroid Hormone Receptor Agonist, MGL-3196, at AASLD Liver Meeting
23 Oct 2017 Reata Announces First Patient Enrolled in Part 2 of MOXIe Study of Omaveloxolone for the Treatment of Friedreich’s Ataxia
23 Oct 2017 Positive Gemcabene Results in Proof-of-Concept Preclinical NASH Study Presented at The Liver Meeting® 2017
23 Oct 2017 CohBar Presents Preclinical Data on CB4209/CB4211 Program for NASH at the AASLD Liver Meeting® 2017
23 Oct 2017 Enanta Pharmaceuticals Announces Positive Phase 1 a/b Clinical Results for its Lead FXR Agonist, EDP-305
23 Oct 2017 Achillion Announces Presentation of Data From OMEGA-1 Phase 2b Trial With Odalasvir, AL-335, and Simeprevir (JNJ-4178) at the 2017 Liver Meeting
23 Oct 2017 Global Blood Therapeutics Announces Discontinuation of Idiopathic Pulmonary Fibrosis (IPF) Program
23 Oct 2017 Antares Pharma Receives Complete Response Letter From the FDA for XYOSTED
23 Oct 2017 Nanobiotix completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma
23 Oct 2017 Novartis combination adjuvant therapy Tafinlar® + Mekinist® receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients
21 Oct 2017 Corbus Pharmaceuticals Reports Positive Topline Results from Phase 2 Study in Rare Autoimmune Disease Dermatomyositis
20 Oct 2017 DURECT Announces Top-line Results from the PERSIST Phase 3 Trial of POSIMIR® (SABER®-Bupivacaine) Did Not Meet Primary Efficacy Endpoint
20 Oct 2017 Spero Therapeutics Initiates Clinical Program for Oral Carbapenem SPR994
20 Oct 2017 Celgene Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Program
19 Oct 2017 Biscayne Neurotherapeutics Reports Successful Phase 1b Clinical Trial Results For Its Novel Antiepileptic Agent
19 Oct 2017 Lycera Announces Advancement of Novel Immuno-Oncology Candidate LYC-55716 RORgamma Agonist into Phase 2a
19 Oct 2017 Esanex Announces First Patient Dosed in an Open-Label Study of SNX-5422 in Chronic Lymphocytic Leukemia
19 Oct 2017 Calithera Announces First Patient Treated in Phase 1 Cohort of INCB01158 dosed in Combination with Keytruda
19 Oct 2017 Tyme’s SM-88 Demonstrates Prolonged Overall Survival in Metastatic Cancer Patients Across Multiple Subgroups
19 Oct 2017 Interim Analysis of Ignyta's Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
18 Oct 2017 Synspira Announces First Patient Dosed in Phase 1a Study of SNSP113 in Cystic Fibrosis
18 Oct 2017 U.S. FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in Metastatic Breast Cancer and Grants Priority Review
17 Oct 2017 Aprea Therapeutics Announces First Patients Enrolled in Phase Ib/II Clinical Study of APR-246 for the Treatment of Esophageal Cancer
17 Oct 2017 MEBIAS Discovery LLC Presents Pre-Clinical Data on Mu Opioid Receptor Pain Compounds at ADDC

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing